The development of potential antibody-based therapies for myeloma

DW Sherbenou, CR Behrens, Y Su, JL Wolf… - Blood reviews, 2015 - Elsevier
With optimal target antigen selection antibody-based therapeutics can be very effective
agents for hematologic malignancies, but none have yet been approved for myeloma.
Rituximab and brentuximab vedotin are examples of success for the naked antibody and
antibody–drug conjugate classes, respectively. Plasma cell myeloma is an attractive disease
for antibody-based targeting due to target cell accessibility and the complementary
mechanism of action with approved therapies. Initial antibodies tested in myeloma were …